Abstract:Background Expression of the long non-coding RNA (lncRNA) LOC285194 was previously shown to be correlated with aggressive clinicopathological features and poor prognosis in several cancers. The aim of the present study was to explore the relationship between LOC285194 expression and clinical outcomes in esophageal squamous cell carcinoma (ESCC), so as to assess whether it could be a novel biomarker for prognosis and prediction of response to therapy on ESCC patients. Methods The method of quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure LOC285194 expression in pretreatment biopsy specimens and matched normal tissue derived from ESCC patients who underwent preoperative chemoradiotherapy followed by surgical resection (CRT + S group; n = 55) or from those who received surgical resection alone (S group; n = 87). The association between LOC285194 expression and clinicopathological features and prognosis were then analyzed. Results LOC285194 expression was significantly down-regulated in ESCC tumor tissues when compared with the adjacent normal tissues ( p < 0.001). Low expression of LOC285194 was associated with larger tumor size (p = 0.002), advanced TNM stage ( p = 0.018), more lymph node metastases ( p = 0.013) and distant metastases ( p = 0.015). In the CRT + S group, the pathological complete response rate was 57% (16/28) for the LOC285194-high group, and 15% (4/27) for the LOC285194-low group. Univariate analysis revealed that low expression of LOC285194 was significantly correlated with CRT response ( p = 0.002). Moreover, Kaplan-Meier survival analysis revealed that patients with low expression of LOC285194 had a decreased disease free survival (DFS) ( p < 0.001) and overall survival (OS) ( p < 0.001). Multivariable analysis further identified low expression of LOC285194 as an independent prognosis factor for CRT response ( p = 0.011), DFS ( p < 0.001) and OS ( p = 0.002). Conclusion Decreased expression of LOC285194 could serve as a molecular marker to predict the clinical outcome of ESCC patients after surgery, and select patients who would benefit from preoperative CRT.

Correlation between expressions of ERCC1/TS mRNA and effects of gastric cancer to chemotherapy in the short term

Relationship Between ERCC1 Expression and Efficacy of Neoadjuvant Chemotherapy in the Patients with Non-Small-cell Lung Cancer

High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.

The Effects of ERCC1 Expression Levels on the Chemosensitivity of Gastric Cancer Cells to Platinum Agents and Survival in Gastric Cancer Patients Treated with Oxaliplatin-Based Adjuvant Chemotherapy

ERCC1 Mrna Levels and Survival of Advanced Gastric Cancer Patients Treated with a Modified FOLFOX Regimen

Expression of ERCC1 and BRCA1 Predict the Clinical Outcome of Non-Small Cell Lung Cancer in Patients Receiving Platinum-Based Chemotherapy.

ERCC1, RRM1 and BRCA1 Mrna Expression Levels and Clinical Outcome of Advanced Non-Small Cell Lung Cancer.

Prognostic Significance of ERCC1 Mrna Expression in Patients with Non-Small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

Predictive Value of ERCC1, ERCC2, and XRCC Expression for Patients with Locally Advanced or Metastatic Gastric Cancer Treated with Neoadjuvant mFOLFOX-4 Chemotherapy

Association of decreased expression of long non-coding RNA LOC285194 with chemoradiotherapy resistance and poor prognosis in esophageal squamous cell carcinoma

[Effect of TUBB3, TS and ERCC1 Mrna Expression on Chemoresponse and Clinical Outcome of Advanced Gastric Cancer by Multiplex Branched-Dna Liquid Chip Technology].

ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

ERCC1 mRNA expression in relation to prognostic of colorectal cancer patients received the standard first-line chemotherapy

High Expression of ERCC1 is a Poor Prognostic Factor in Chinese Patients with Non-Small Cell Lung Cancer Receiving Cisplatin-Based Therapy

Expression of RRM1 and ERCC1 Genes in Tumor Tissues and Peripheral Blood Lymphocytes of Advanced Non-Small Cell Lung Cancer

The clinical significance of ERCC1 in predicting the response to platinum-based chemoradiotherapy and prognosis of esophageal squamous cell carcinoma

Correlated Analysis of 5 Fluorouracil Metabolic Enzymes with Tumor Response after SOX Regimen Neoadjuvant Chemotherapy in Advanced Gastric Cancer

Relationship Between Expression of ERCC1 and Effect of Platinum-based Chemotherapy in Patients with Advanced NSCLC

Positive Expression of ERCC1 Predicts a Poorer Platinum-Based Treatment Outcome in Chinese Patients with Advanced Non-Small-cell Lung Cancer

Effects of Expression of ERCC1, RRM1 on Survival Trend of Lung Cancer with Cisplatin Combine Gemcitabine Chemotherapy after Surgical Resection.]

The Expression of TS,ERCC1 in Colorectal Carcinoma and Their Clinical Significance